e-learning
resources
Amsterdam 2011
Monday, 26.09.2011
Clinical features of pulmonary hypertension
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Childhood pulmonary arterial hypertension: Insights from REVEAL
R. Barst, D. Ivy, C. G. Elliott, P. Wason, A. Foreman, D. Miller, M. McGoon (New York, Aurora, Murray, South San Francisco, San Francisco, Rochester, United States Of America)
Source:
Annual Congress 2011 - Clinical features of pulmonary hypertension
Session:
Clinical features of pulmonary hypertension
Session type:
Thematic Poster Session
Number:
2327
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. Barst, D. Ivy, C. G. Elliott, P. Wason, A. Foreman, D. Miller, M. McGoon (New York, Aurora, Murray, South San Francisco, San Francisco, Rochester, United States Of America). Childhood pulmonary arterial hypertension: Insights from REVEAL. Eur Respir J 2011; 38: Suppl. 55, 2327
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: respiratory care for newborns in resource-limited settings
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Risk assessment in pulmonary arterial hypertension (PAH): Insights from the GRIPHON study
Source: International Congress 2018 – Risk stratification in treatment of pulmonary arterial hypertension
Year: 2018
REVEAL: a contemporary US pulmonary arterial hypertension registry
Source: Eur Respir Rev 2012; 21: 8-18
Year: 2012
Global burden of chronic thromboembolic pulmonary hypertension (CTEPH): An epidemiological analysis
Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension
Year: 2014
Molecular study of genetic modifiers in patients with pulmonary arterial hypertension
Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Year: 2014
Specific pulmonary arterial hypertension therapy in COPD patients with severe pulmonary hypertension
Source: International Congress 2014 – Pulmonary hypertension in lung disease
Year: 2014
Quality of life of patients with pulmonary arterial hypertension associated with congenital heart disease: The multicenter cross-sectional ACHILLE study
Source: International Congress 2014 – Pulmonary hypertension: clinical management
Year: 2014
Risk assessment in pulmonary arterial hypertension
Source: Eur Respir J, 51 (3) 1800279; 10.1183/13993003.00279-2018
Year: 2018
Risk assessment in pulmonary arterial hypertension
Source: Eur Respir Rev 2016; 25: 390-398
Year: 2016
Risk assessment in pulmonary arterial hypertension
Source: Eur Respir J, 51 (3) 1702606; 10.1183/13993003.02606-2017
Year: 2018
Exercise-induced pulmonary hypertension in patients with systemic sclerosis: Pilot-study
Source: International Congress 2014 – Pulmonary hypertension: clinical management
Year: 2014
Would RDW be a prognostic factor in pulmonary arterial hypertension?
Source: International Congress 2014 – Pulmonary hypertension: clinical management
Year: 2014
Long-term data from the Swiss pulmonary hypertension registry
Source: International Congress 2014 – Pulmonary hypertension: clinical management
Year: 2014
LATE-BREAKING ABSTRACT: Riociguat for the treatment of pulmonary arterial hypertension (PAH): 2-year results from the PATENT-2 long-term extension
Source: International Congress 2014 – New technologies and biomarkers in lung disease
Year: 2014
Pulmonary arterial hypertension – A single-centre experience
Source: International Congress 2014 – Pulmonary hypertension: clinical management
Year: 2014
Unique characteristics of patients with pulmonary arterial hypertension associated with congenital heart disease compared to the rest of pulmonary arterial hypertension subgroups
Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology
Year: 2014
Pulmonary arterial hypertension in Adult-Onset Still’s Disease
Source: Virtual Congress 2021 – All about pulmonary arterial hypertension
Year: 2021
HbA1c-levels in patients with operable chronic thromboembolic pulmonary hypertension
Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension
Year: 2014
Risk status at selexipag initiation in pulmonary arterial hypertension (PAH): Insights from EXPOSURE
Source: Virtual Congress 2020 – Clinical evaluation, biomarkers and risk assessment of pulmonary hypertension
Year: 2020
Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN
Source: Eur Respir J 2015; 46: 1711-1720
Year: 2015
Correlations between clinical variables and quality of life in pulmonary arterial hypertension
Source: International Congress 2014 – Pulmonary hypertension: clinical management
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept